Status
Conditions
Treatments
About
ST-segment elevation myocardial infarction (STEMI) is a major cause of morbidity and mortality worldwide. In spite of decrease in acute and long-term mortality following STEMI in parallel with more use of reperfusion therapy, such as primary percutaneous coronary intervention (PPCI), modern antithrombotic therapy, and secondary prevention, mortality remains considerable. Reduced EF is a well-known predictor of increased short and long term major adverse cardiovascular events MACE :( heart failure, stroke and death)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
204 participants in 1 patient group
Loading...
Central trial contact
Aly Tohamy, MD; Ayman Khairy, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal